Advertisement


Lee S. Schwartzberg, MD: 2017 Update on ICLIO: Adopting Immunotherapy in the Community Setting

2017 ASCO Annual Meeting

Advertisement

Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.



Related Videos

Supportive Care

Viviane Hess, MD, on Managing Stress in Newly Diagnosed Patients

Viviane Hess, MD, of the University of Basel and University Hospital Basel, discusses a Web-based stress management tool, called STREAM, designed to reduce stress and improve quality of life for newly diagnosed cancer patients, who often lack psychological support. (Abstract LBA10002)

Hematologic Malignancies

David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)

CNS Cancers

Eric Jonasch, MD, on Von-Hippel Lindau Disease: Pazopanib Trial

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the study. (Abstract 4516)

Lung Cancer

Taofeek K. Owonikoko, MD, PhD, on SCLC: Results of the ECOG-ACRIN 2511 Trial

Taofeek K. Owonikoko, MD, PhD, of Emory University, discusses study findings on cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer. (Abstract 8505)

Prostate Cancer

Neeraj Agarwal, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on the LATITUDE Trial

Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

Advertisement

Advertisement




Advertisement